quantisnow
FeedTopReportsPricing
⌘K
Live feed
09:00:00·43d
PRRelease
Indivior Pharmaceuticals Inc. logo

New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder

INDV· Indivior Pharmaceuticals Inc.
Health Care
Original source

Companies

  • INDV
    Indivior Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Aug 6UpdateH.C. Wainwright$27.00
  • Jul 22UpdateJefferies$20.00
  • Jan 28UpdateRodman & Renshaw$16.00
  • Jul 23UpdatePiper Sandler$22.00
  • Apr 3UpdateCraig Hallum$37.00
  • Jul 13UpdateNorthland Capital$35.00

Related

  • PR7d
    Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse
  • PR14d
    Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
  • PR23d
    New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
  • SEC27d
    SEC Form DEFA14A filed by Indivior Pharmaceuticals Inc.
  • SEC27d
    SEC Form DEF 14A filed by Indivior Pharmaceuticals Inc.
  • SEC31d
    SEC Form SCHEDULE 13G filed by Indivior Pharmaceuticals Inc.
  • INSIDER37d
    Chief Financial Officer Preblick Ryan converted options into 6,302 shares and covered exercise/tax liability with 2,843 shares, increasing direct ownership by 1% to 320,751 units (SEC Form 4)
  • SEC37d
    Indivior Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022